


# **PARTICIPATING IN CLINICAL TRIALS**

**An Introduction to Clinical Trials**

**Glossary of Clinical Trial Terms**

**Lupus Clinical Trial Opportunities**



# **An Introduction to Clinical Trials**

Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

## **What is a clinical trial?**

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people and ways to improve health. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings. There are strict rules for clinical trials, which are monitored by the National Institutes of Health and the U.S. Food and Drug Administration.

## **Why participate in a clinical trial?**

Participants in clinical trials can play a more active role in their own health care, gain access to promising new research treatments before they are widely available, and help others with the same disease by contributing to both current and future medical research.

## **Who can participate in a clinical trial?**

All clinical trials have guidelines about who can participate. Using [inclusion/exclusion criteria](#) is an important principle of medical research that helps to produce reliable results. The factors that allow someone to participate in a clinical trial are called "inclusion criteria" and those that disallow someone from participating are called "exclusion criteria". These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. Before joining a clinical trial, a participant must qualify for the study. Some research studies seek participants with illnesses or conditions to be studied in the clinical trial, while others need healthy participants. It is important to note that inclusion and exclusion criteria are not used to reject people personally. Instead, the criteria are used to identify appropriate participants and keep them safe. The criteria help ensure that researchers will be able to answer the questions they plan to study.

## **What happens during a clinical trial?**

The clinical trial process depends on the kind of trial being conducted (See [What are the different types of clinical trials?](#)) The clinical trial team includes doctors and nurses as well as social workers and other health care professionals. They check the health of the participant at the beginning of the trial, give specific instructions for participating in the trial, monitor the participant carefully during the trial, and stay in touch after the trial is completed.

Some clinical trials involve more tests and doctor visits than the participant would normally have for an illness or condition. For all types of trials, the participant works with a research team. Clinical trial participation is most successful when the [protocol](#) is carefully followed and there is frequent contact with the research staff.

## **What is informed consent?**

Informed consent is the process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. If the participant's native language is not English, translation assistance can be provided. Then the research team provides an [informed consent document](#) that includes details about the study, such as its purpose, duration, required procedures, medications and key contacts. Expected outcomes, possible risks, and potential benefits are explained in the informed consent document. The participant then decides whether or not to sign the document. Informed consent is not a contract, and the participant may withdraw from the trial at any time.

Clinical research trial staff will review the informed consent statement with you and answer your questions. If you decide to participate after reviewing the statement and talking with staff and family members, you will need to sign the informed consent statement. Your signature indicates that you understand the study and agree to participate voluntarily.

## **What are the benefits and risks of participating in a clinical trial?**

It is important to understand that some risks are involved in clinical research, just as in routine medical care and activities of daily living. In thinking about the risks of research, it is helpful to focus on two things: the degree of harm that could result from taking part in the study, and the chance of any harm occurring. Most clinical studies pose risks of minor discomfort, lasting only a short time. Some volunteer subjects, however, experience complications that require medical attention. The specific risks associated with any research protocol are described in detail in the consent document, which you are asked to sign before taking part in research. In addition, the major risks of participating in a study will be explained to you by a member of the research team, who will answer your questions about the study. Before deciding to participate, you should carefully weigh these risks against possible benefits. You may or may not receive direct benefit for yourself and your condition as a result of participating in research, but in either case, you will know that the knowledge developed may help others.

Other research may provide only indirect benefit to the patient by giving researchers information that may be an important first step toward developing a treatment. For example, research may show how a disease progresses or how it affects others systems in the body.

### **Benefits**

Clinical trials that are well designed and well executed are the best approach for eligible participants to:

- Play an active role in their personal health care.
- Gain access to promising new research treatments before they are widely available.
- Obtain expert medical care from a team of doctors, nurses, technicians, and support staff at leading health care facilities during the trial.
- Help others by contributing to medical research.

### **Risks**

There are risks to clinical trials.

- There may be unpleasant, serious or even life-threatening side effects to experimental treatment.
- The experimental treatment may not be effective for the participant.
- The [protocol](#) may require more of their time and attention than would a non-protocol treatment, including trips to the study site, more treatments, hospital stays or complex dosage requirements.

### **What are side effects and adverse reactions?**

Side effects are any undesired actions or effects of the experimental drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental treatments must be evaluated for both immediate and long-term side effects.

### **How is the safety of the participant protected?**

Many protections and safeguards for volunteer patients are built into the Clinical Trial process. It may help alleviate some of your fears about participating in a clinical study to know what some of these are:

***The Patient Bill of Rights.*** All patients who take part in clinical trial studies are protected by the [Patient Bill of Rights](#), developed by the American Hospital Association for use in hospitals across the country. The Patients' Bill of Rights contains guidelines to ensure privacy and confidentiality of patients and their medical records.

***Hospital Accreditation.*** As in any medical research facility, an institutional review board (IRB) must review and approve every new study at NIH before the study can begin. The IRB is made up of medical specialists, statisticians, nurses, social workers, medical ethicists, and members of the community. The IRB reviews protocols to ensure patient safety. In addition, The [Joint Commission on Accreditation of Healthcare Organizations](#) (JCAHO), periodically reviews the Clinical Research Center hospital to see if stringent standards, leading to JCAHO accreditation, have been met.

Every clinical trial in the U.S. must be approved and monitored by an [Institutional Review Board](#) (IRB) to make sure the risks are as low as possible and are worth any potential benefits. An IRB is an independent committee of physicians, statisticians, community advocates, and others that ensures that a clinical trial is ethical and the rights of study participants are protected. All institutions that conduct or support biomedical research involving people must, by federal regulation, have an IRB that initially approves and periodically reviews the research.

The ethical and legal codes that govern medical practice also apply to clinical trials. In addition, most clinical research is federally regulated with built in safeguards to protect the participants. The trial follows a carefully controlled protocol, a study plan which details what researchers will do in the study. As a clinical trial progresses, researchers report the results of the trial at scientific meetings, to medical journals, and to various government agencies. Individual participants' names will remain secret and will not be mentioned in these reports (See [Confidentiality Regarding Trial Participants](#)).

### **What should people consider before participating in a trial?**

People should know as much as possible about the clinical trial and feel comfortable asking the members of the health care team questions about it, the care expected while in a trial, and the cost of the trial. The following questions might be helpful for the participant to discuss with the health care team. Some of the answers to these questions are found in the informed consent document.

- What is the purpose of the study?
- Who is going to be in the study?
- Why do researchers believe the experimental treatment being tested may be effective? Has it been tested before?
- Will the study benefit others?
- What kinds of tests and experimental treatments are involved?
- What is required of me?
- What is my role in the study—am I a healthy volunteer or a patient volunteer?
- How do the possible risks, side effects, and benefits in the study compare with my current treatment?
- Will the study directly benefit me?
- How might this trial affect my daily life?
- What discomforts and inconveniences are involved?
- How long will the trial last?
- Will hospitalization be required?
- Who will pay for the experimental treatment?
- Will I be reimbursed for other expenses?
- What type of long-term follow up care is part of this study?
- How will I know that the experimental treatment is working? Will results of the trials be provided to me?
- Who will be in charge of my care?
- Have I discussed participation in the study with those who are important to me, such as family and friends?
- Do I wish to participate in the study?

**What kind of preparation should a potential participant make for the meeting with the research coordinator or doctor?**

- Plan ahead and write down possible questions to ask.
- Ask a friend or relative to come along for support and listen to the responses to the questions.
- Bring a tape recorder to record the discussion to replay later.

**Does a participant continue to work with a primary health care provider while in a trial?**

Yes. Most clinical trials provide short-term treatments related to a designated illness or condition, but do not provide extended or complete primary health care. In addition, by having the health care provider work with the research team, the participant can ensure that other medications or treatments will not conflict with the [protocol](#).

**Can a participant leave a clinical trial after it has begun?**

Yes. A participant can leave a clinical trial, at any time. When withdrawing from the trial, the participant should let the research team know about it, and the reasons for leaving the study.

**Where do the ideas for trials come from?**

Ideas for clinical trials usually come from researchers. After researchers test new therapies or procedures in the laboratory and in animal studies, the experimental treatments with the most promising laboratory results are moved into clinical trials. During a trial, more and more information is gained about an experimental treatment, its risks, and how well it may or may not work.

## **Who sponsors clinical trials?**

Clinical trials are sponsored or funded by a variety of organizations or individuals such as physicians, medical institutions, foundations, voluntary groups, and pharmaceutical companies, in addition to federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veteran's Affairs (VA). Trials can take place in a variety of locations, such as hospitals, universities, doctors' offices, or community clinics.

## **What is a protocol?**

A protocol is a study plan on which all clinical trials are based. The plan is carefully designed to safeguard the health of the participants as well as answer specific research questions. A protocol describes what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study. While in a clinical trial, participants following a protocol are seen regularly by the research staff to monitor their health and to determine the safety and effectiveness of their treatment.

## **What is a placebo?**

A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the experimental treatment's effectiveness. In some studies, the participants in the [control group](#) will receive a placebo instead of an active drug or experimental treatment.

## **What is a control or control group?**

A control is the standard by which experimental observations are evaluated. In many clinical trials, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo.

## **What are the different types of clinical trials?**

[Treatment trials](#) test experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.

[Prevention trials](#) look for better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vitamins, vaccines, minerals, or lifestyle changes.

[Diagnostic trials](#) are conducted to find better tests or procedures for diagnosing a particular disease or condition.

[Screening trials](#) test the best way to detect certain diseases or health conditions.

[Quality of Life trials](#) (or Supportive Care trials) explore ways to improve comfort and the quality of life for individuals with a chronic illness.

## What are the phases of clinical trials?

Clinical trials are conducted in phases. The trials at each phase have a different purpose and help scientists answer different questions:

In [Phase I trials](#), researchers test an experimental drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

In [Phase II trials](#), the experimental study drug or treatment is given to a larger group of people (100-300) to learn more about side effects, how the body uses the drug, to see if it is effective and to further evaluate its safety.

In [Phase III trials](#), the experimental study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.

In [Phase IV trials](#), post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

## What is an "expanded access" protocol?

Most human use of [investigational new drugs](#) takes place in [controlled clinical trials](#) conducted to assess safety and [efficacy](#) of new drugs. Data from the trials can serve as the basis for the drug marketing application. Sometimes, patients do not qualify for these carefully controlled trials because of other health problems, age, or other factors. For patients who may benefit from the drug use but don't qualify for the trials, [FDA](#) regulations enable manufacturers of investigational new drugs to provide for "expanded access" use of the drug. For example, a [treatment IND](#) (Investigational New Drug application) or treatment protocol is a relatively unrestricted study. The primary intent of a treatment IND/protocol is to provide for access to the new drug for people with a life-threatening or serious disease for which there is no good alternative treatment. A secondary purpose for a treatment IND/protocol is to generate additional information about the drug, especially its safety. Expanded access protocols can be undertaken only if clinical investigators are actively studying the experimental treatment in well-controlled studies, or all studies have been completed. There must be evidence that the drug may be an effective treatment in patients like those to be treated under the protocol. The drug cannot expose patients to unreasonable risks given the severity of the disease to be treated.

Some investigational drugs are available from pharmaceutical manufacturers through expanded access programs listed in [ClinicalTrials.gov](#). Expanded access protocols are generally managed by the manufacturer, with the investigational treatment administered by researchers or doctors in office-based practice. If you or a loved one are interested in treatment with an investigational drug under an expanded access protocol listed in [ClinicalTrials.gov](#), review the protocol [eligibility criteria](#) and location information and inquire at the Contact Information number.

# Glossary of Clinical Trial Terms

The following glossary was prepared to help the consumer become familiar with the most common terms used in clinical trials.

**ADVERSE REACTION:** (Adverse Event.) An unwanted effect caused by the administration of drugs. Onset may be sudden or develop over time (See [Side Effects](#)).

**ADVOCACY AND SUPPORT GROUPS:** Organizations and groups that actively support participants and their families with valuable resources, including self-empowerment and survival tools.

**APPROVED DRUGS:** In the U.S., the Food and Drug Administration (FDA) must approve a substance as a drug before it can be marketed. The approval process involves several steps including pre-clinical laboratory and animal studies, clinical trials for safety and efficacy, filing of a New Drug Application by the manufacturer of the drug, FDA review of the application, and FDA approval/rejection of application (See [Food and Drug Administration](#)).

**ARM:** Any of the treatment groups in a randomized trial. Most randomized trials have two "arms," but some have three "arms," or even more (See [Randomized Trial](#)).

**BASELINE:** 1. Information gathered at the beginning of a study from which variations found in the study are measured. 2. A known value or quantity with which an unknown is compared when measured or assessed. 3. The initial time point in a clinical trial, just before a participant starts to receive the experimental treatment which is being tested. At this reference point, measurable values such as CD4 count are recorded. Safety and efficacy of a drug are often determined by monitoring changes from the baseline values.

**BIAS:** When a point of view prevents impartial judgment on issues relating to the subject of that point of view. In clinical studies, bias is controlled by blinding and randomization (See [Blind](#) and [Randomization](#)).

**BLIND:** A randomized trial is "Blind" if the participant is not told which arm of the trial he is on. A clinical trial is "Blind" if participants are unaware on whether they are in the experimental or control arm of the study; also called masked. (See [Single Blind Study](#) and [Double Blind Study](#)).

**CLINICAL:** Pertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science.

**CLINICAL ENDPOINT:** See [Endpoint](#).

**CLINICAL INVESTIGATOR:** A medical researcher in charge of carrying out a clinical trial's protocol.

**CLINICAL TRIAL:** A clinical trial is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials (also called medical research and research studies) are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase I tests a new drug or treatment in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people; and Phase IV takes place after the drug or treatment has been licensed and marketed. (See [Phase I](#), [II](#), [III](#), and [IV Trials](#)).

**COHORT:** In epidemiology, a group of individuals with some characteristics in common.

**COMMUNITY-BASED CLINICAL TRIAL (CBCT):** A clinical trial conducted primarily through primary-care physicians rather than academic research facilities.



**COMPASSIONATE USE:** A method of providing experimental therapeutics prior to final FDA approval for use in humans. This procedure is used with very sick individuals who have no other treatment options. Often, case-by-case approval must be obtained from the FDA for "compassionate use" of a drug or therapy.

**COMPLEMENTARY AND ALTERNATIVE THERAPY:** Broad range of healing philosophies, approaches, and therapies that Western (conventional) medicine does not commonly use to promote well-being or treat health conditions. Examples include acupuncture, herbs, etc. Internet Address: <http://www.nccam.nih.gov>.

**CONFIDENTIALITY REGARDING TRIAL PARTICIPANTS:** Refers to maintaining the confidentiality of trial participants including their personal identity and all personal medical information. The trial participants' consent to the use of records for data verification purposes should be obtained prior to the trial and assurance must be given that confidentiality will be maintained.

**CONTRAINDICATION:** A specific circumstance when the use of certain treatments could be harmful.

**CONTROL:** A control is the nature of the intervention control.

**CONTROL GROUP:** The standard by which experimental observations are evaluated. In many clinical trials, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo (See [Placebo](#) and [Standard Treatment](#)).

**CONTROLLED TRIALS:** Control is a standard against which experimental observations may be evaluated. In clinical trials, one group of participants is given an experimental drug, while another group (i.e., the control group) is given either a standard treatment for the disease or a placebo.

**DATA SAFETY AND MONITORING BOARD (DSMB):** An independent committee, composed of community representatives and clinical research experts, that reviews data while a clinical trial is in progress to ensure that participants are not exposed to undue risk. A DSMB may recommend that a trial be stopped if there are safety concerns or if the trial objectives have been achieved.

**DIAGNOSTIC TRIALS:** Refers to trials that are conducted to find better tests or procedures for diagnosing a particular disease or condition. Diagnostic trials usually include people who have signs or symptoms of the disease or condition being studied.

**DOSE-RANGING STUDY:** A clinical trial in which two or more doses of an agent (such as a drug) are tested against each other to determine which dose works best and is least harmful.

**DOUBLE-BLIND STUDY:** A clinical trial design in which neither the participating individuals nor the study staff knows which participants are receiving the experimental drug and which are receiving a placebo (or another therapy). Double-blind trials are thought to produce objective results, since the expectations of the doctor and the participant about the experimental drug do not affect the outcome; also called double-masked study. See [Blinded Study](#), [Single-Blind Study](#), and [Placebo](#).

**DOUBLE-MASKED STUDY:** See [Double-Blind Study](#).

**DRUG-DRUG INTERACTION:** A modification of the effect of a drug when administered with another drug. The effect may be an increase or a decrease in the action of either substance, or it may be an adverse effect that is not normally associated with either drug.

**DSMB:** See [Data Safety and Monitoring Board](#).

**EFFICACY:** (Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the procedure mandated by the FDA, Phase II clinical trials gauge efficacy, and Phase III trials confirm it (See [Food and Drug Administration \(FDA\), Phase II and III Trials](#)).

**ELIGIBILITY CRITERIA:** Summary criteria for participant selection; includes Inclusion and Exclusion criteria. (See [Inclusion/Exclusion Criteria](#))

**EMPIRICAL:** Based on experimental data, not on a theory.

**ENDPOINT:** Overall outcome that the protocol is designed to evaluate. Common endpoints are severe toxicity, disease progression, or death.

**EPIDEMIOLOGY:** The branch of medical science that deals with the study of incidence and distribution and control of a disease in a population.

**EXCLUSION/INCLUSION CRITERIA:** See [Inclusion/Exclusion Criteria](#).

**EXPANDED ACCESS:** Refers to any of the FDA procedures, such as compassionate use, parallel track, and treatment IND that distribute experimental drugs to participants who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials.

**EXPERIMENTAL DRUG:** A drug that is not FDA licensed for use in humans, or as a treatment for a particular condition (See [Off-Label Use](#)).

**FDA:** See [Food and Drug Administration](#).

**FOOD AND DRUG ADMINISTRATION (FDA):** The U.S. Department of Health and Human Services agency responsible for ensuring the safety and effectiveness of all drugs, biologics, vaccines, and medical devices, including those used in the diagnosis, treatment, and prevention of HIV infection, AIDS, and AIDS-related opportunistic infections. The FDA also works with the blood banking industry to safeguard the nation's blood supply. Internet address: <http://www.fda.gov/>.

**HYPOTHESIS:** A supposition or assumption advanced as a basis for reasoning or argument, or as a guide to experimental investigation.

**INCLUSION/EXCLUSION CRITERIA:** The medical or social standards determining whether a person may or may not be allowed to enter a clinical trial. These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. It is important to note that inclusion and exclusion criteria are not used to reject people personally, but rather to identify appropriate participants and keep them safe.

**IND:** See [Investigational New Drug](#).

**INFORMED CONSENT:** The process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study.

**INFORMED CONSENT DOCUMENT:** A document that describes the rights of the study participants, and includes details about the study, such as its purpose, duration, required procedures, and key contacts. Risks and potential benefits are explained in the informed consent document. The participant then decides whether or not to sign the document. Informed consent is not a contract, and the participant may withdraw from the trial at any time.

**INSTITUTIONAL REVIEW BOARD (IRB):** 1. A committee of physicians, statisticians, researchers, community advocates, and others that ensures that a clinical trial is ethical and that the rights of study participants are protected. All clinical trials in the U.S. must be approved by an IRB before they begin. 2. Every institution that conducts or supports biomedical or behavioral research involving human participants must, by federal regulation, have an IRB that initially approves and periodically reviews the research in order to protect the rights of human participants.

**INTENT TO TREAT:** Analysis of clinical trial results that includes all data from participants in the groups to which they were randomized ( See [Randomization](#)) even if they never received the treatment.

**INTERVENTION NAME:** The generic name of the precise intervention being studied.

**INTERVENTIONS:** Primary interventions being studied: types of interventions are Drug, Gene Transfer, Vaccine, Behavior, Device, or Procedure.

**INVESTIGATIONAL NEW DRUG:** A new drug, antibiotic drug, or biological drug that is used in a clinical investigation. It also includes a biological product used *in vitro* for diagnostic purposes.

**IRB:** See [Institutional Review Board](#).

**MASKED:** The knowledge of intervention assignment. See [Blind](#)

**NATURAL HISTORY STUDY:** Study of the natural development of something (such as an organism or a disease) over a period of time.

**NEW DRUG APPLICATION (NDA):** An application submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed - for a license to market the drug for a specified indication.

**OFF-LABEL USE:** A drug prescribed for conditions other than those approved by the FDA.

**OPEN-LABEL TRIAL:** A clinical trial in which doctors and participants know which drug or vaccine is being administered.

**ORPHAN DRUGS:** An FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications.

**PEER REVIEW:** Review of a clinical trial by experts chosen by the study sponsor. These experts review the trials for scientific merit, participant safety, and ethical considerations.

**PHARMACOKINETICS:** The processes (in a living organism) of absorption, distribution, metabolism, and excretion of a drug or vaccine.

**PHASE I TRIALS:** Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

**PHASE II TRIALS:** Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.

**PHASE III TRIALS:** Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide an adequate basis for physician labeling.

**PHASE IV TRIALS:** Post-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use.

**PLACEBO:** A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. (See [Placebo Controlled Study](#)).

**PLACEBO CONTROLLED STUDY:** A method of investigation of drugs in which an inactive substance (the placebo) is given to one group of participants, while the drug being tested is given to another group. The results obtained in the two groups are then compared to see if the investigational treatment is more effective in treating the condition.

**PLACEBO EFFECT:** A physical or emotional change, occurring after a substance is taken or administered, that is not the result of any special property of the substance. The change may be beneficial, reflecting the expectations of the participant and, often, the expectations of the person giving the substance.

**PRECLINICAL:** Refers to the testing of experimental drugs in the test tube or in animals - the testing that occurs before trials in humans may be carried out.

**PREVENTION TRIALS:** Refers to trials to find better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vitamins, vaccines, minerals, or lifestyle changes.

**PROTOCOL:** A study plan on which all clinical trials are based. The plan is carefully designed to safeguard the health of the participants as well as answer specific research questions. A protocol describes what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study. While in a clinical trial, participants following a protocol are seen regularly by the research staff to monitor their health and to determine the safety and effectiveness of their treatment (See [Inclusion/Exclusion Criteria](#)).

**QUALITY OF LIFE TRIALS (or Supportive Care trials):** Refers to trials that explore ways to improve comfort and quality of life for individuals with a chronic illness.

**RANDOMIZATION:** A method based on chance by which study participants are assigned to a treatment group. Randomization minimizes the differences among groups by equally distributing people with particular characteristics among all the trial arms. The researchers do not know which treatment is better. From what is known at the time, any one of the treatments chosen could be of benefit to the participant (See [Arm](#)).

**RANDOMIZED TRIAL:** A study in which participants are randomly (i.e., by chance) assigned to one of two or more treatment arms of a clinical trial. Occasionally placebos are utilized. (See [Arm](#) and [Placebo](#)).

**RISK-BENEFIT RATIO:** The risk to individual participants versus the potential benefits. The risk/benefit ratio may differ depending on the condition being treated.

**SCREENING TRIALS:** Refers to trials which test the best way to detect certain diseases or health conditions.

**SIDE EFFECTS:** Any undesired actions or effects of a drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental drugs must be evaluated for both immediate and long-term side effects (See [Adverse Reaction](#)).

**SINGLE-BLIND STUDY:** A study in which one party, either the investigator or participant, is unaware of what medication the participant is taking; also called single-masked study. (See [Blind](#) and [Double-Blind Study](#)).

**SINGLE-MASKED STUDY:** See [Single-Blind Study](#).

**STANDARD TREATMENT:** A treatment currently in wide use and approved by the FDA, considered to be effective in the treatment of a specific disease or condition.

**STANDARDS OF CARE:** Treatment regimen or medical management based on state of the art participant care.

**STATISTICAL SIGNIFICANCE:** The probability that an event or difference occurred by chance alone. In clinical trials, the level of statistical significance depends on the number of participants studied and the observations made, as well as the magnitude of differences observed.

**STUDY ENDPOINT:** A primary or secondary outcome used to judge the effectiveness of a treatment.

**STUDY TYPE:** The primary investigative techniques used in an observational protocol; types are Purpose, Duration, Selection, and Timing.

**TOXICITY:** An adverse effect produced by a drug that is detrimental to the participant's health. The level of toxicity associated with a drug will vary depending on the condition which the drug is used to treat.

**TREATMENT IND:** IND stands for Investigational New Drug application, which is part of the process to get approval from the FDA for marketing a new prescription drug in the U.S. It makes promising new drugs available to desperately ill participants as early in the drug development process as possible. Treatment INDs are made available to participants before general marketing begins, typically during Phase III studies. To be considered for a treatment IND a participant cannot be eligible to be in the definitive clinical trial.

**TREATMENT TRIALS:** Refers to trials that test new treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.

## Learn About Clinical Trial Opportunities

- To learn about lupus clinical research trial opportunities go to [www.clinicaltrials.gov](http://www.clinicaltrials.gov)
- Type **lupus erythematosus** in the search box and click on the search button.
- Then click on the **Results on Map** tab at the top.
- Click on the **Geographic Area or State** you are interested in and the studies for that area will be listed.
- Click on a specific study for details about the trial's purpose, study eligibility, inclusion and exclusion criteria, locations, and contact information.

# Clinical Trial Opportunities

## **Aspreva Pharmaceuticals Seeks People with Lupus Nephritis**

The Aspreva Lupus Management Study (ALMS) is being conducted to assess the efficacy and safety of mycophenolate mofetil (MMF) versus standard therapy in inducing a response and maintaining remission in patients with Lupus Nephritis. The study involves two phases. The first phase is a 6-month induction period to initially treat Lupus Nephritis. If a response is achieved, patients will then enter the second phase which is a 3 year maintenance period. This study is recruiting in approximately 40 centers across North America with a target to enroll 100 patients.

For more information, please contact Aspreva's medical information toll-free at 011-800 111-25252 or access the study website at [www.almstudy.com](http://www.almstudy.com) or [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and search lupus nephritis.

## **Bristol-Myers Squibb**

The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, active lupus flares in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints. All subjects will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.

For more information: BMS Call Center 1-866-892-1BMS Ext. 175 or visit [www.ClinicalTrials.gov/show/NCT00119678](http://www.ClinicalTrials.gov/show/NCT00119678)

## **La Jolla Pharmaceutical Company**

Lupus Clinical Trial: an ongoing clinical trial entitled "A Randomized Double-blind, Placebo-controlled, Four-arm, Parallel-group, Multicenter, Multinational Safety and Efficacy Trial of 100mg and 300mg of LJP 394 in Systemic Lupus Erythematosus Patients with a History of Renal Disease." The primary purpose of this study is to determine whether LJP 394 is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.

In some patients with SLE, certain types of white blood cells called lymphocytes make substances called double stranded DNA antibodies that may cause inflammation of the body's own tissues. These double stranded DNA antibodies may also be associated with lupus kidney disease. The study drug is designed to remove the double stranded DNA antibodies from circulation. The study drug may also attach to certain white blood cells involved in making these antibodies. When the study drug was given to lupus subjects in earlier studies, double stranded DNA antibodies were lowered.

For more information call 1-858-452-6600 or visit [www.clinicaltrials.gov/show/NCT00089804](http://www.clinicaltrials.gov/show/NCT00089804)

## **Genentech Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus**

This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in adults with Systemic **Lupus Erythematosus**.

Official Title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic **Lupus Erythematosus**.

For more information 1-866-510-0092 or visit [www.ClinicalTrials.gov/show/NCT00541749](http://www.ClinicalTrials.gov/show/NCT00541749)

## **A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis**

Genentech's LUNAR Trial is a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with MMF compared with placebo in combination with mycophenolate mofetil (MMF) in subjects diagnosed with ISN/RPS 2003 Class III or IV Lupus Nephritis.

If you would like to learn more about this study visit [www.clinicaltrials.gov/show/NCT00282347](http://www.clinicaltrials.gov/show/NCT00282347) or call 1-888-662-6728

## **Genentech Recruiting for Clinical Trial for Treatment of Lupus**

Genentech's EXPLORER study will enroll approximately 250 people with lupus at more than 55 centers nationwide. The Phase II/III study will focus on the safety and efficacy of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in people with moderate to severe lupus. The primary efficacy endpoint of the randomized, double blind, placebo-controlled trial will be evaluated at 52 weeks. EXPLORER is looking for participants who are currently diagnosed with SLE, between the ages of 16 and 75, and experiencing an active disease flare. Patients must be stable using one immunosuppressive drug, and not pregnant or nursing.

For more information, call 1-888-662-6728 or visit [www.clinicaltrials.gov/show/NCT00137969](http://www.clinicaltrials.gov/show/NCT00137969)

## **UCB**

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose of the study is to evaluate safety and long term efficacy in concert with standard SLE treatments. Official Title: A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems. The primary objective is to continue to gather long- term safety data on patients with moderate to severe flaring SLE.

For more information: 1 877 822 9493 or visit [www.ClinicalTrials.gov/show/NCT00383513](http://www.ClinicalTrials.gov/show/NCT00383513)

## **Human Genome Sciences Advances Belimumab into Phase 3 Clinical Trials for Systemic Lupus Erythematosus**

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) have initiated Phase 3 clinical trials of belimumab in Systemic Lupus Erythematosus (SLE). Belimumab is a human monoclonal antibody that specifically recognizes and inhibits the biologic activity of B-Lymphocyte stimulator, or BLYS®. The Phase 3 trials were designed by HGS in collaboration with GSK and leading international SLE experts, and aim to enroll more than 1600 patients with active SLE. This is understood to be the largest clinical trial program undertaken to-date researching a new drug in this disease. Human Genome Sciences has met with both the U.S. Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMA), and has received agreement on the major components of the Phase 3 program including the primary efficacy endpoint measures, target patient population and dose selection.

Human Genome Sciences is a biopharmaceutical company with a mission to apply great science and great medicine to deliver innovative drugs to patients with unmet medical needs. Early clinical and preclinical results to-date have demonstrated the potential efficacy and safety of belimumab, enabling progression to the Phase 3 program.

This Phase 3 development program will include two double-blind, placebo controlled, multi-center Phase 3 superiority trials, BLISS-52 and BLISS-76, which will evaluate the efficacy and safety of belimumab plus standard of care, versus placebo plus standard of care, in the treatment of patients with active SLE. BLISS (Belimumab International SLE Study) is looking to enroll patients that are at least 18 years old, have been diagnosed with lupus, and have been on stable treatment for the last month.

If you would like to learn more about the BLISS (Belimumab International SLE Study) studies, visit [www.clinicaltrials.gov/show/NCT00410384](http://www.clinicaltrials.gov/show/NCT00410384) or call Human Genome Sciences at 1-866-447-9749.

## **National Institute of Allergy and Infectious Diseases (NIAID) Recruiting Patients for Trial of Etanercept for the Treatment of Lupus Nephritis**

Systemic **lupus erythematosus** (SLE) is a chronic, multisystem, autoimmune disease in which the body's immune system attacks its own normal tissues. This abnormal autoimmune response can result in damage to many parts of the body, including the skin, joints, lungs, heart, brain, intestines, and kidneys. Kidney problems occur in 60-75 % of **lupus** patients. The development of **lupus**-related kidney disease (called **lupus nephritis**) is associated with an overall worse prognosis.

SLE is usually treated with drugs that try to block inflammation caused by the immune system. These treatments can create their own problems and they do not cure **lupus**. The drugs that are often used to treat **lupus nephritis** include prednisone (steroids), cyclophosphamide (Cytosan), azathioprine (AZA or Imuran), and mycophenolate mofetil (MMF or Cellcept). The main purpose of this study is to evaluate the safety and tolerability of etanercept compared to placebo in combination with standard of care to treat individuals with active **lupus nephritis**.

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-Alpha Using Etanercept

For more information visit [www.ClinicalTrials.gov/show/NCT00447265](http://www.ClinicalTrials.gov/show/NCT00447265)



## **DISCLAIMER**

**It is the policy of The Lupus Foundation of Mid and Northern New York, Inc. to provide information on Lupus and related diseases that have been developed by physicians, and other healthcare providers and medical professionals. The opinions and statements expressed by the contributors to this document do not necessarily reflect the opinions or positions of the Lupus Foundation of Mid and Northern NY. The material contained in this publication is provided for informational purposes only and does not imply endorsement of any specific product, clinical research trial, company, and/or organization. We oppose self-diagnosis and self-treatment and urge readers to discuss any concerns they may have regarding diagnosis and treatment with their own healthcare providers.**

**Making the choice to participate in a clinical trial is a very, very personal decision that should be based on discussions with family members and treating physicians familiar with the patient's history. We cannot emphasize this point strongly enough.**

**Lupus Foundation of Mid and Northern New York, Inc., would like to thank Kathleen Arntsen and Sandra Frear for their efforts in developing this resource material and the education program for the May 2006 "Hope is on the Horizon" Education Symposium. All rights reserved. This material may not be copied or published without the express written consent of the Lupus Foundation of Mid and Northern New York, Inc. We acknowledge the following for contributing information and resource material for this document:**

**NIH Clinical Center**

**<http://clinicalcenter.nih.gov/>**

**A service of the US NIH—Clinical Trials**

**<http://www.clinicaltrials.gov/ct/info/resources>**

**United States National Library of Medicine, National Institutes of Health**

**<http://www.nlm.nih.gov/>**

**Office of Research on Women's Health, Office of the NIH Director, National Institutes of Health/DHHS**

**<http://orwh.od.nih.gov/>**

# Lupus Ends With Us!

